ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Research Report 2026
Published Date: 2026-04-10
|
Report Code: QYRE-Auto-12J9107
Home | Market Reports
Global Irritable Bowel Syndrome with Diarrhea IBS D Drugs Market Outlook 2022
BUY CHAPTERS

Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Research Report 2026

Code: QYRE-Auto-12J9107
Report
2026-04-10
Pages:114
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Bausch Health
Allergan plc
Sebela Pharmaceuticals
Astellas Pharmaceuticals
Amneal pharms
Pharscin Pharma

Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size

The global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market was valued at US$ 1862 million in 2025 and is anticipated to reach US$ 3757 million by 2032, at a CAGR of 10.7% from 2026 to 2032.

Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market

Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market

The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.
Irritable bowel syndrome (IBS) is a common disorder that affects the large intestine. Signs and symptoms include cramping, abdominal pain, bloating, gas, and diarrhea or constipation, or both. IBS is a chronic condition that need to manage long term.
IBS that causes increased diarrhea is often called IBS-D. Diarrhea predominant irritable bowel syndrome (IBS-D) is a subtype of IBS in which a person experiences frequent episodes of diarrhea with accompanying abdominal pain. Like IBS, IBS-D is a functional gastrointestinal disorder (FGD) in that there is no visible disease, inflammation, or injury to account for its symptoms. It is estimated that approximately a third of people who have IBS experience the disorder with diarrhea as the predominant bowel habit.
In this report, we study the drugs for diarrhea predominant irritable bowel syndrome (IBS-D).
North America is the largest consumption place of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs, followed by Europe. The two account for more than 80% of the consumer market in together. The most used IBS-D drug is XIFAXAN, accounting for more than 60% of the market share, followed by Viberzi and Lotronex. IBS-D drugs are widely sold through hospital pharmacies and retail pharmacies.
This report delivers a comprehensive overview of the global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs. The Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market size, estimates, and forecasts are provided in terms of sales volume (K Units) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market comprehensively. Regional market sizes by Type, by Sales Channel, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Sales Channel, and by region.
Market Segmentation

Scope of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Report

Report Metric Details
Report Name Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market
Accounted market size in 2025 US$ 1862 million
Forecasted market size in 2032 US$ 3757 million
CAGR 10.7%
Base Year 2025
Forecasted years 2026 - 2032
Segment by Type
  • XIFAXAN
  • Viberzi
  • Lotronex
  • Other
  • by Sales Channel
  • Hospitals Pharmacy
  • Retail Pharmacy
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Bausch Health, Allergan, Sebela Pharmaceuticals, Astellas Pharmaceuticals, Amneal Pharms, Pharscin Pharma
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Sales Channel, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
  • Chapter 2: Provides a detailed analysis of the competitive landscape for Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
  • Chapter 3: Examines Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
  • Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
  • Chapter 5: Analyzes market segments by Sales Channel, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
  • Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
  • Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
  • Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
  • Chapter 9: Summarizes the key findings and conclusions of the report.

FAQ for this report

How fast is Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market growing?

Ans: The Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market witnessing a CAGR of 10.7% during the forecast period 2026-2032.

What is the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market size in 2032?

Ans: The Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market size in 2032 will be US$ 3757 million.

Who are the main players in the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market report?

Ans: The main players in the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market are Bausch Health, Allergan, Sebela Pharmaceuticals, Astellas Pharmaceuticals, Amneal Pharms, Pharscin Pharma

What are the Type segmentation covered in the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market report?

Ans: The Types covered in the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market report are XIFAXAN, Viberzi, Lotronex, Other, by Sales Channel, Hospitals Pharmacy, Retail Pharmacy

1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Overview
1.1 Product Definition
1.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Type
1.2.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Value by Type: 2025 vs 2032
1.2.2 XIFAXAN
1.2.3 Viberzi
1.2.4 Lotronex
1.2.5 Other
1.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Sales Channel
1.3.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Value by Sales Channel: 2025 vs 2032
1.3.2 Hospitals Pharmacy
1.3.3 Retail Pharmacy
1.3.4 Other
1.4 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size Estimates and Forecasts
1.4.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue 2021–2032
1.4.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales 2021–2032
1.4.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Competition by Manufacturers
2.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Manufacturers (2021–2026)
2.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs, Product Types and Applications
2.7 Global Key Manufacturers of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs, Date of Entry into the Industry
2.8 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Competitive Situation and Trends
2.8.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Players Market Share by Revenue
2.8.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Scenario by Region
3.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region: 2021–2032
3.2.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region: 2021–2026
3.2.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region: 2027–2032
3.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Region: 2021–2032
3.3.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Region: 2021–2026
3.3.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Region: 2027–2032
3.4 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Facts & Figures by Country
3.4.1 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2021–2032)
3.4.3 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2021–2032)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Facts & Figures by Country
3.5.1 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2021–2032)
3.5.3 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Facts & Figures by Region
3.6.1 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region (2021–2032)
3.6.3 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Facts & Figures by Country
3.7.1 Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2021–2032)
3.7.3 Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2021–2032)
3.8.3 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2021–2032)
4.1.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2021–2026)
4.1.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2027–2032)
4.1.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Type (2021–2032)
4.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type (2021–2032)
4.2.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type (2021–2026)
4.2.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type (2027–2032)
4.2.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Type (2021–2032)
4.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Type (2021–2032)
5 Segment by Sales Channel
5.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Sales Channel (2021–2032)
5.1.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Sales Channel (2021–2026)
5.1.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Sales Channel (2027–2032)
5.1.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Sales Channel (2021–2032)
5.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Sales Channel (2021–2032)
5.2.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Sales Channel (2021–2026)
5.2.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Sales Channel (2027–2032)
5.2.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Sales Channel (2021–2032)
5.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Sales Channel (2021–2032)
6 Key Companies Profiled
6.1 Bausch Health
6.1.1 Bausch Health Company Information
6.1.2 Bausch Health Description and Business Overview
6.1.3 Bausch Health Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Bausch Health Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio
6.1.5 Bausch Health Recent Developments/Updates
6.2 Allergan
6.2.1 Allergan Company Information
6.2.2 Allergan Description and Business Overview
6.2.3 Allergan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Allergan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio
6.2.5 Allergan Recent Developments/Updates
6.3 Sebela Pharmaceuticals
6.3.1 Sebela Pharmaceuticals Company Information
6.3.2 Sebela Pharmaceuticals Description and Business Overview
6.3.3 Sebela Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Sebela Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio
6.3.5 Sebela Pharmaceuticals Recent Developments/Updates
6.4 Astellas Pharmaceuticals
6.4.1 Astellas Pharmaceuticals Company Information
6.4.2 Astellas Pharmaceuticals Description and Business Overview
6.4.3 Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio
6.4.5 Astellas Pharmaceuticals Recent Developments/Updates
6.5 Amneal Pharms
6.5.1 Amneal Pharms Company Information
6.5.2 Amneal Pharms Description and Business Overview
6.5.3 Amneal Pharms Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 Amneal Pharms Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio
6.5.5 Amneal Pharms Recent Developments/Updates
6.6 Pharscin Pharma
6.6.1 Pharscin Pharma Company Information
6.6.2 Pharscin Pharma Description and Business Overview
6.6.3 Pharscin Pharma Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 Pharscin Pharma Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio
6.6.5 Pharscin Pharma Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industry Chain Analysis
7.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production Mode & Process Analysis
7.4 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Marketing
7.4.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Channels
7.4.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Distributors
7.5 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Customer Analysis
8 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Dynamics
8.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industry Trends
8.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Drivers
8.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Challenges
8.4 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Bausch Health
Allergan plc
Sebela Pharmaceuticals
Astellas Pharmaceuticals
Amneal pharms
Pharscin Pharma
List of Tables
 Table 1. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Value by Type (US$ Million), 2025 vs 2032
 Table 2. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Value by Sales Channel (US$ Million), 2025 vs 2032
 Table 3. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Competitive Situation by Manufacturers in 2025
 Table 4. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units) of Key Manufacturers (2021–2026)
 Table 5. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Manufacturers (2021–2026)
 Table 6. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (US$ Million) by Manufacturers (2021–2026)
 Table 7. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Share by Manufacturers (2021–2026)
 Table 8. Global Market Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Average Price (USD/Unit) of Key Manufacturers (2021–2026)
 Table 9. Global Key Players of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs, Industry Ranking, 2023 vs 2024 vs 2025
 Table 10. Global Key Manufacturers of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs, Manufacturing Sites and Headquarters
 Table 11. Global Key Manufacturers of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs, Product Types and Applications
 Table 12. Global Key Manufacturers of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs, Date of Entry into the Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Companies by Tier (Tier 1, Tier 2, Tier 3), based on Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue, 2025
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
 Table 17. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region (K Units), 2021–2026
 Table 18. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Region (2021–2026)
 Table 19. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region (K Units), 2027–2032
 Table 20. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Region (2027–2032)
 Table 21. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Region (US$ Million), 2021–2026
 Table 22. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Region (2021–2026)
 Table 23. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Region (US$ Million), 2027–2032
 Table 24. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Region (2027–2032)
 Table 25. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 26. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (K Units), 2021–2026
 Table 27. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (K Units), 2027–2032
 Table 28. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (US$ Million), 2021–2026
 Table 29. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (US$ Million), 2027–2032
 Table 30. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 31. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (K Units), 2021–2026
 Table 32. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (K Units), 2027–2032
 Table 33. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (US$ Million), 2021–2026
 Table 34. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (US$ Million), 2027–2032
 Table 35. Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
 Table 36. Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region (K Units), 2021–2026
 Table 37. Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region (K Units), 2027–2032
 Table 38. Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Region (US$ Million), 2021–2026
 Table 39. Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Region (US$ Million), 2027–2032
 Table 40. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 41. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (K Units), 2021–2026
 Table 42. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (K Units), 2027–2032
 Table 43. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (US$ Million), 2021–2026
 Table 44. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (US$ Million), 2027–2032
 Table 45. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 46. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (K Units), 2021–2026
 Table 47. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (K Units), 2027–2032
 Table 48. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (US$ Million), 2021–2026
 Table 49. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (US$ Million), 2027–2032
 Table 50. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units) by Type (2021–2026)
 Table 51. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units) by Type (2027–2032)
 Table 52. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Type (2021–2026)
 Table 53. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Type (2027–2032)
 Table 54. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (US$ Million) by Type (2021–2026)
 Table 55. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (US$ Million) by Type (2027–2032)
 Table 56. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Type (2021–2026)
 Table 57. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Type (2027–2032)
 Table 58. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price (USD/Unit) by Type (2021–2026)
 Table 59. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price (USD/Unit) by Type (2027–2032)
 Table 60. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units) by Sales Channel (2021–2026)
 Table 61. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units) by Sales Channel (2027–2032)
 Table 62. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Sales Channel (2021–2026)
 Table 63. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Sales Channel (2027–2032)
 Table 64. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (US$ Million) by Sales Channel (2021–2026)
 Table 65. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (US$ Million) by Sales Channel (2027–2032)
 Table 66. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Sales Channel (2021–2026)
 Table 67. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Sales Channel (2027–2032)
 Table 68. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price (USD/Unit) by Sales Channel (2021–2026)
 Table 69. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price (USD/Unit) by Sales Channel (2027–2032)
 Table 70. Bausch Health Company Information
 Table 71. Bausch Health Description and Business Overview
 Table 72. Bausch Health Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
 Table 73. Bausch Health Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product
 Table 74. Bausch Health Recent Developments/Updates
 Table 75. Allergan Company Information
 Table 76. Allergan Description and Business Overview
 Table 77. Allergan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
 Table 78. Allergan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product
 Table 79. Allergan Recent Developments/Updates
 Table 80. Sebela Pharmaceuticals Company Information
 Table 81. Sebela Pharmaceuticals Description and Business Overview
 Table 82. Sebela Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
 Table 83. Sebela Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product
 Table 84. Sebela Pharmaceuticals Recent Developments/Updates
 Table 85. Astellas Pharmaceuticals Company Information
 Table 86. Astellas Pharmaceuticals Description and Business Overview
 Table 87. Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
 Table 88. Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product
 Table 89. Astellas Pharmaceuticals Recent Developments/Updates
 Table 90. Amneal Pharms Company Information
 Table 91. Amneal Pharms Description and Business Overview
 Table 92. Amneal Pharms Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
 Table 93. Amneal Pharms Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product
 Table 94. Amneal Pharms Recent Developments/Updates
 Table 95. Pharscin Pharma Company Information
 Table 96. Pharscin Pharma Description and Business Overview
 Table 97. Pharscin Pharma Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
 Table 98. Pharscin Pharma Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product
 Table 99. Pharscin Pharma Recent Developments/Updates
 Table 100. Key Raw Materials Lists
 Table 101. Raw Materials Key Suppliers Lists
 Table 102. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Distributors List
 Table 103. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Customers List
 Table 104. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Trends
 Table 105. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Drivers
 Table 106. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Challenges
 Table 107. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Restraints
 Table 108. Research Programs/Design for This Report
 Table 109. Key Data Information from Secondary Sources
 Table 110. Key Data Information from Primary Sources
 Table 111. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs
 Figure 2. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Value by Type (US$ Million), 2021–2032
 Figure 3. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Share by Type: 2025 & 2032
 Figure 4. XIFAXAN Product Picture
 Figure 5. Viberzi Product Picture
 Figure 6. Lotronex Product Picture
 Figure 7. Other Product Picture
 Figure 8. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Value by Sales Channel (US$ Million), 2021–2032
 Figure 9. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Share by Sales Channel: 2025 & 2032
 Figure 10. Hospitals Pharmacy
 Figure 11. Retail Pharmacy
 Figure 12. Other
 Figure 13. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue, (US$ Million), 2021 vs 2025 vs 2032
 Figure 14. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size (US$ Million), 2021–2032
 Figure 15. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units), 2021–2032
 Figure 16. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Average Price (USD/Unit), 2021–2032
 Figure 17. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Report Years Considered
 Figure 18. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Share by Manufacturers in 2025
 Figure 19. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Share by Manufacturers in 2025
 Figure 20. Top 5 and Top 10 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Players: Market Share by Revenue in Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs in 2025
 Figure 21. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
 Figure 22. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
 Figure 23. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Country (2021–2032)
 Figure 24. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Country (2021–2032)
 Figure 25. U.S. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 26. Canada Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 27. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Country (2021–2032)
 Figure 28. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Country (2021–2032)
 Figure 29. Germany Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 30. France Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 31. U.K. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 32. Italy Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 33. Russia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 34. Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Region (2021–2032)
 Figure 35. Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Region (2021–2032)
 Figure 36. China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 37. Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 38. South Korea Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 39. India Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 40. Australia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 41. Taiwan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 42. Indonesia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 43. Thailand Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 44. Malaysia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 45. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Country (2021–2032)
 Figure 46. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Country (2021–2032)
 Figure 47. Mexico Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 48. Brazil Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 49. Argentina Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 50. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Country (2021–2032)
 Figure 51. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Country (2021–2032)
 Figure 52. Turkey Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 53. Saudi Arabia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 54. UAE Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 55. Global Sales Market Share of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Type (2021–2032)
 Figure 56. Global Revenue Market Share of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Type (2021–2032)
 Figure 57. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price (USD/Unit) by Type (2021–2032)
 Figure 58. Global Sales Market Share of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Sales Channel (2021–2032)
 Figure 59. Global Revenue Market Share of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Sales Channel (2021–2032)
 Figure 60. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price (USD/Unit) by Sales Channel (2021–2032)
 Figure 61. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Chain
 Figure 62. Channels of Distribution (Direct Vs Distribution)
 Figure 63. Bottom-up and Top-down Approaches for This Report
 Figure 64. Data Triangulation
 Figure 65. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic

$2900

Single User License
Electronic

$4350

Multi User License
Electronic

$5800

Enterprise License
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Leap India

SIMILAR REPORTS

Irritable Bowel Syndrome Treatment Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Irritable Bowel Syndrome IBS Market Insights Forecast to 2030
Irritable Bowel Syndrome Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Irritable Bowel Syndrome IBS Diagnostics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Rx Irritable Bowel Syndrome IBS Drugs Market Insights Forecast to 2030
Global Irritable Bowel Syndrome with Constipation Drugs Market Research Report 2024
Global Gastrointestinal Sales Market Report Competitive Analysis and Regional Opportunities 2025 2031
Global IBS Probiotic Supplement Market Research Report 2024
Global Gastrointestinal Therapeutics Market Research Report 2024
Global Functional Dyspepsia Drug Market Insights Forecast to 2030
Global Gastrointestinal Drugs Market Research Report 2025
Global Irritable Bowel Syndrome Drug Market Research Report 2024
Global Crohn s Disease Market Research Report 2024
Global Peptide Based Gastrointestinal Disorders Therapeutics Market Research Report 2024
Global Prescription Gastrointestinal Drugs Market Research Report 2024
Global In vitro Inflammatory Bowel Disease Diagnostic Market Research Report 2024
Inflammatory Bowel Disease Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Eluxadoline API Market Research Report 2024
Global Irritable Bowel Syndrome Medication Market Research Report 2025
Global Digestive Drugs Market Insights Forecast to 2030
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions